...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Tropical Medicine and Hygiene >Safety, Tolerability, and Compliance with Long-Term Antimalarial Chemoprophylaxis in American Soldiers in Afghanistan
【24h】

Safety, Tolerability, and Compliance with Long-Term Antimalarial Chemoprophylaxis in American Soldiers in Afghanistan

机译：阿富汗美军士兵的安全性，耐受性和长期抗疟药物化学疗法的依从性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Long-term antimalarial chemoprophylaxis is currently used by deployed U.S. military personnel. Previous small, short-term efficacy studies have shown variable rates of side effects among patients taking various forms of chemoprophylaxis, though reliable safety and tolerability data on long-term use are limited. We conducted a survey of troops returning to Fort Drum, NY following a 12-month deployment to Operation Enduring Freedom, Afghanistan from 2006 to 2007. Of the 2,351 respondents, 95% reported taking at least one form of prophylaxis during their deployment, and 90% were deployed for > 10 months. Compliance with daily doxycycline was poor (60%) compared with 80% with weekly mefloquine (MQ). Adverse events (AEs) were reported by approximately 30% with both MQ and doxycycline, with 10% discontinuing doxycycline compared with 4% of MO users. Only 6% and 31% of soldiers reported use of bed nets and skin repellents, respectively. Compliance with long-term malaria prophylaxis was poor, and there were substantial tolerability issues based on these anonymous survey results, though fewer with MO than doxycycline. Given few long-term antimalarial chemoprophylaxis options, there is an unmet medical need for new anti-malarials safe for long-term use.
机译：部署的美国军事人员目前正在使用长期的抗疟药化学预防。先前的小型短期疗效研究表明，采取各种形式的化学预防药物的患者中，副作用的发生率不同，尽管长期使用的可靠安全性和耐受性数据有限。我们对2006年至2007年部署到阿富汗持久自由行动12个月后返回纽约州Fort Drum的部队进行了调查。在2,351名受访者中，有95％的人报告在部署期间采取了至少一种预防措施，其中90％ ％被部署了> 10个月。每日强力霉素的依从性较差（60％），而每周甲氟喹（MQ）的依从性为80％。据报道，MQ和强力霉素的不良事件（AEs）约为30％，停用强力霉素的停用率为10％，而MO用户为4％。分别只有6％和31％的士兵报告使用了蚊帐和驱蚊剂。长期预防疟疾的依从性很差，基于这些匿名调查结果，存在很大的耐受性问题，尽管MO的患者少于强力霉素。由于很少有长期抗疟药物的化学预防选择，因此对于可以长期使用的安全新型抗疟药物的医疗需求尚未得到满足。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号